Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06089941 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas

Study acronym: PTCL-SEQ
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Collaborators expanded, about 1 wordv3
  2. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Nov 2, 2025 to Nov 4, 2025
    • Study completion date: Nov 2, 2026 to Nov 4, 2026
    • Start date changed from estimate of Nov 2, 2023 to Jan 1, 2024
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the feasibility of analyzing circulating tumor DNA (ctDNA) as a biomarker using the shallow whole genome sequencing (lpWGS) technique coupled with deep sequencing of a targeted panel of genes (NGS), in a population of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma (PTCL).
Trial Details
NCT Number NCT06089941
Lead Sponsor Centre Henri Becquerel
Collaborators: IDEOGEN
Conditions
(from sponsor)		 Peripheral T Cell Lymphoma
Related terms Lymphoma, T-Cell, Peripheral
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov